Aug 6 (Reuters) - Steris ( STE ) reported

better-than-expected profit and revenue for the first quarter on

Tuesday, as strong demand for non-urgent medical procedures

lifted sales of its surgical and examination tools.

The Dublin, Ireland-based company, which offers devices such

as surgical tables, examination lights and endoscope, has been

seeing strong sales of its products since late last year as more

people opt for surgical treatments that were deferred during the

pandemic.

Steris' ( STE ) revenue was at $1.3 billion for the quarter ended

June 30, compared with analysts' average estimate of $1.27

billion, according to LSEG data.

Its healthcare segment, the company's biggest by revenue,

grew 10% during the period.

The company's adjusted profit was $2.03 per share, compared

with the estimates of $1.98 per share.

Steris ( STE ) reiterated its adjusted earnings per share forecast

for the fiscal 2025 in the range of $9.05 to $9.25. It also

maintained its annual revenue growth projection of 6.5%-7.5%.